Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulationROSATO, R. R; DAI, Y; ALMENARA, J. A et al.Leukemia. 2004, Vol 18, Num 11, pp 1780-1788, issn 0887-6924, 9 p.Article

Small-molecule cyclin-dependent kinase modulatorsSENDEROWICZ, Adrian M.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6609-6620, issn 0950-9232, 12 p.Article

P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agentsRADHAKRISHNAN, S. K; BHAT, U. G; HALAS, M et al.Oncogene (Basingstoke). 2008, Vol 27, Num 9, pp 1306-1309, issn 0950-9232, 4 p.Article

Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent processYUN DAI; RAHMANI, Mohamed; GRANT, Steven et al.Oncogene (Basingstoke). 2003, Vol 22, Num 46, pp 7108-7122, issn 0950-9232, 15 p.Article

Flavopiridol: where do we stand in chronic lymphocytic leukemia?LIN, T. S; PORCU, And P.Leukemia. 2004, Vol 18, Num 2, pp 243-246, issn 0887-6924, 4 p.Article

Inhibition of cyclin-dependent kinases is neuroprotective in 1-methyl-4-phenylpyridinium-induced apoptosis in neuronsALVIRA, D; TAJES, M; VERDAGUER, E et al.Neuroscience. 2007, Vol 146, Num 1, pp 350-365, issn 0306-4522, 16 p.Article

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolSHAPIRO, Geoffrey I.Clinical cancer research. 2004, Vol 10, Num 12, pp 4270s-4275s, issn 1078-0432, 2Conference Paper

Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumorsFORNIER, M. N; RATHKOPF, D; SHAH, M et al.Clinical cancer research. 2007, Vol 13, Num 19, pp 5841-5846, issn 1078-0432, 6 p.Article

Chemistry of biologically important flavonesVERMA, Alok K; PRATAP, Ram.Tetrahedron (Oxford. Print). 2012, Vol 68, Num 41, issn 0040-4020, 8517, 8523-8538 [17 p.]Article

Fusarium proliferatum, an endophytic fungus from Dysoxylum binectariferum Hook.f, produces rohitukine, a chromane alkaloid possessing anti-cancer activityMOHANA KUMARA, Patel; ZUEHLKE, Sebastian; PRITI, Vaidyanathan et al.Antonie van Leeuwenhoek. 2012, Vol 101, Num 2, pp 323-329, issn 0003-6072, 7 p.Article

Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cellsALI, Shadan; EL-RAYES, Basil F; ARANHA, Olivia et al.Breast cancer research and treatment. 2005, Vol 90, Num 1, pp 25-31, issn 0167-6806, 7 p.Article

Cyclosporin A enhances colchicine-induced apoptosis in rat cerebellar granule neuronsCANUDAS, Anna Maria; JORDA, Elvira G; VERDAGUER, Ester et al.British journal of pharmacology. 2004, Vol 141, Num 4, pp 661-669, issn 0007-1188, 9 p.Article

A novel liposomal formulation of flavopiridolXIAOJUAN YANG; XIAOBIN ZHAO; DALTON, James T et al.International journal of pharmaceutics (Print). 2009, Vol 365, Num 1-2, pp 170-174, issn 0378-5173, 5 p.Article

Assaying pharmacodynamic endpoints with targeted therapy: Flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemiaLIWEN WANG; HARSHMAN, Sean W; SHUJUN LIU et al.Proteomics (Weinheim. Print). 2010, Vol 10, Num 23, pp 4281-4292, issn 1615-9853, 12 p.Article

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBYRD, John C; LIN, Thomas S; BROERING, Sarah et al.Blood. 2007, Vol 109, Num 2, pp 399-404, issn 0006-4971, 6 p.Article

Flavopiridol blocks integrin-mediated survival in Dormant Breast cancer cellsNAJMI, Saltanat; KORAH, Reju; CHANDRA, Rachna et al.Clinical cancer research. 2005, Vol 11, Num 5, pp 2038-2046, issn 1078-0432, 9 p.Article

A phase i clinical trial of the sequential combination of irinotecan followed by flavopiridolSHAH, Manish A; KORTMANSKY, Jeremy; O'REILLY, Eileen et al.Clinical cancer research. 2005, Vol 11, Num 10, pp 3836-3845, issn 1078-0432, 10 p.Article

Rhabdoid Tumor Growth is Inhibited by FlavopiridolSMITH, Melissa E; CIMICA, Velasco; CHINNI, Srinivasa et al.Clinical cancer research. 2008, Vol 14, Num 2, pp 523-532, issn 1078-0432, 10 p.Article

Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluidsRICHARD, Christina; MATTHEWS, Donald; DUIVENVOORDEN, Wilhelmina et al.Clinical cancer research. 2005, Vol 11, Num 9, pp 3523-3529, issn 1078-0432, 7 p.Article

Abrogation of p21 expression by Flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cellsNGUYEN, Dao M; SCHRUMP, William D; CHEN, G. Aaron et al.Clinical cancer research. 2004, Vol 10, Num 5, pp 1813-1825, issn 1078-0432, 13 p.Article

Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponseMASON, Kathy A; HUNTER, Nancy R; RAJU, Uma et al.International journal of radiation oncology, biology, physics. 2004, Vol 59, Num 4, pp 1181-1189, issn 0360-3016, 9 p.Article

Comparative drug screening in NUT midline carcinomaBEESLEY, A. H; STIRNWEISS, A; FERRARI, E et al.British journal of cancer. 2014, Vol 110, Num 5, pp 1189-1198, issn 0007-0920, 10 p.Article

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approachSTEPHENS, Deborah M; RUPPERT, Amy S; BLUM, Kristie et al.Haematologica (Roma). 2012, Vol 97, Num 3, pp 423-427, issn 0390-6078, 5 p.Article

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemiasBLUM, William; PHELPS, Mitch A; JOHNSON, Amy et al.Haematologica (Roma). 2010, Vol 95, Num 7, pp 1098-1105, issn 0390-6078, 8 p.Article

Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors : A Children's Oncology Group StudyWHITLOCK, James A; KRAILO, Mark; REID, Joel M et al.Journal of clinical oncology. 2005, Vol 23, Num 36, pp 9179-9186, issn 0732-183X, 8 p.Article